[HTML][HTML] Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan
Y Osugi, H Iwata, Y Imai, D Kobayashi, R Hirashima - Cureus, 2022 - ncbi.nlm.nih.gov
Aim: This study aimed to report clinical courses of patients who had mild coronavirus
disease 2019 (COVID-19), defined as SpO 2 of 96 or higher, and treated with/without …
disease 2019 (COVID-19), defined as SpO 2 of 96 or higher, and treated with/without …
The effect of casirivimab with imdevimab on disease progression in nonsevere COVID‐19 patients in a single hospital in Japan
J Komagamine, T Yabuki, S Yoshihara… - Journal of General …, 2022 - Wiley Online Library
Background Recent randomized trials have revealed that neutralizing monoclonal
antibodies can reduce disease progression in mild–moderate COVID‐19 patients. However …
antibodies can reduce disease progression in mild–moderate COVID‐19 patients. However …
Risk factors for progression to acute respiratory failure after casirivimab and imdevimab administration: A retrospective study
N Ito, Y Kitahara, K Miwata, M Okimoto… - Respiratory Investigation, 2022 - Elsevier
Background Casirivimab and imdevimab are effective in preventing hospitalization in
outpatients with coronavirus disease 2019 (COVID-19); however, disease progression after …
outpatients with coronavirus disease 2019 (COVID-19); however, disease progression after …
[HTML][HTML] Efficacy and safety of casirivimab-imdevimab combination on COVID-19 patients: A systematic review and meta-analysis randomized controlled trial
Background The advantages and disadvantages of casirivimab-imdevimab for coronavirus
disease 2019 are not well understood. We conducted a systematic review and meta …
disease 2019 are not well understood. We conducted a systematic review and meta …
[HTML][HTML] Casirivimab-imdevimab treatment is associated with reduced rates of mortality and hospitalization in patients with COVID-19: A systematic review with meta …
M Gao, G Ao, X Hao, B Xie - The Journal of Infection, 2023 - ncbi.nlm.nih.gov
We read with great interest that monoclonal antibody (mAb) cocktail may serve as an
effective and targeted therapeutic strategy in the treatment of patients with COVID-19. 1 …
effective and targeted therapeutic strategy in the treatment of patients with COVID-19. 1 …
[HTML][HTML] Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19
RR Razonable, C Pawlowski, JC O'Horo, LL Arndt… - …, 2021 - thelancet.com
Background Real-world clinical data to support the use of casirivimab–imdevimab for the
treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is …
treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is …
COMPARING THE EFFECTIVENESS AND SAFETY OF CASIRIVIMAB/IMDEVIMAB WITH BAMLANIVIMAB IN PATIENTS WITH COVID-19: A SYSTEMATIC REVIEW …
M Karimi Babaahmadi, M Mohajeri… - Studies in Medical …, 2024 - umj.umsu.ac.ir
Background & Aims: Casirivimab/imdevimab and bamlanivimab are monoclonal antibodies
that are used in the treatment of patients with COVID-19. The aim of the present study was to …
that are used in the treatment of patients with COVID-19. The aim of the present study was to …
Association of subcutaneous or intravenous route of administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in COVID-19
EK McCreary, JR Bariola, RJ Wadas, JA Shovel… - medRxiv, 2021 - medrxiv.org
Importance Monoclonal antibody (mAb) treatment decreases hospitalization and death in
outpatients with mild to moderate COVID-19; however, only intravenous administration has …
outpatients with mild to moderate COVID-19; however, only intravenous administration has …
[PDF][PDF] Effects of Casirivimab and Imdevimab on Symptom Outcomes in Outpatients with COVID-19
Y Wang, M Hussein, D Rofail, KJ Lin, DJ Conrado… - Age (years) - croiconference.org
Effects of Casirivimab and Imdevimab on Symptom Outcomes in Outpatients with COVID-19
Page 1 Conclusions Presented at the Conference on Retroviruses and Opportunistic Infections …
Page 1 Conclusions Presented at the Conference on Retroviruses and Opportunistic Infections …
Impact of a subcutaneous casirivimab and imdevimab clinic in outpatients with symptomatic COVID-19: A single-center, propensity-matched cohort study
C Rhudy, S Bochenek, J Thomas… - American Journal of …, 2023 - academic.oup.com
Purpose To evaluate the success of a clinic for subcutaneous administration of casirivmab
and imdevimab (REGEN-COV; Regeneron) for treatment of patients with symptomatic mild …
and imdevimab (REGEN-COV; Regeneron) for treatment of patients with symptomatic mild …
相关搜索
- casirivimab imdevimab covid 19
- casirivimab imdevimab meta analysis
- casirivimab imdevimab clinical prognosis
- clinical prognosis mild covid
- clinical outcomes covid 19
- casirivimab imdevimab hospitalization in patients
- casirivimab imdevimab coronavirus disease
- administration of casirivimab clinical outcomes
- hospitalization in patients covid 19
- casirivimab imdevimab reduced rates
- reduced rates covid 19
- route of administration covid 19
- casirivimab imdevimab belgian experience
- casirivimab imdevimab efficacy and safety
- belgian experience covid 19
- meta analysis covid 19